Three years ago, the Red House shop and cafe was just a bunch of pictures on a vision board. Now, Pescod is standing inside the building, watching customers chatting over coffee and reading newspapers ...

Adel (ADEL), which is jointly developing an Alzheimer's disease drug candidate with Oscotec, said on the 16th that it signed a technology transfer agreement with French drugmaker Sanofi to transfer ...

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and licensed to Sanofi. The ADEL-Sanofi agreement is valued at over $1.04 billion ...

Korean biopharmaceutical company Adel announced Monday that it has secured a license-out agreement worth up to $1.04 billion with multinational health care firm Sanofi for the development and ...

Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody therapy designed to treat Alzheimer's disease. The French pharma is paying ...

The south coast gun was awarded the Laurie Daley Cup Most Valuable Player and the Illawarra South Coast Dragons Player of the Year awards. Treweek was an instrumental member of the Dragons side that ...

Tonight will be largely dry with mostly cloudy skies at first. The cloud will thin during the early hours to reveal lengthy clear spells. A cold and icy night. Saturday Tomorrow will be largely dry ...

Candy paint an sky high wheel stands are coming to Cook County. The Southeast Gasser Association will be racing at South Georgia Motorsports Park (SGMP). Right now its unknown how the cow managed to ...

ADEL Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases, has entered into an exclusive worldwide license agreement with Sanofi, a multinational ...

Deal includes $80 million upfront payment, with total potential value up to $1.04 billion plus royalties ADEL grants exclusive worldwide rights for acetylated tau-targeting antibody 'ADEL-Y01' to ...

Shares in Sanofi rose 2% to €82.27 ($96.87) at market open on 16 December. LCV via Shutterstock.com. Following the disappointment of a multiple sclerosis (MS) trial readout this week, Sanofi has ...